{"result": "(\"entity\"<|>REAL DECRETO 1090/2015<|>ORGANIZATION<|>Real Decreto 1090/2015 is the legislation that regulates clinical trials with medications in Spain, focusing on ethical and methodological standards for trials.)\n##\n(\"entity\"<|>AGENCIA ESPAÑOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS<|>ORGANIZATION<|>The Agencia Española de Medicamentos y Productos Sanitarios is the Spanish Agency responsible for the regulation and oversight of medications and clinical trials.)\n##\n(\"entity\"<|>DECLARACIÓN DE HELSINKI<|>ORGANIZATION<|>The Declaration of Helsinki outlines ethical principles for medical research involving human subjects, ensuring the safety and rights of participants.)\n##\n(\"entity\"<|>LEY ORGÁNICA 15/1999<|>ORGANIZATION<|>Ley Orgánica 15/1999 is the Spanish law concerning the protection of personal data, ensuring the privacy of individuals involved in clinical trials.)\n##\n(\"entity\"<|>ENSAYOS CLÍNICOS<|>EVENT<|>Clinical trials are research studies that test new medications or treatments to determine their safety and efficacy.)\n##\n(\"entity\"<|>ESTUDIOS POSTAUTORIZACIÓN<|>EVENT<|>Post-authorization studies are observational studies conducted after a medication has been approved for use, focusing on its long-term effects and safety.)\n##\n(\"relationship\"<|>REAL DECRETO 1090/2015<|>AGENCIA ESPAÑOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS<|>Real Decreto 1090/2015 is regulated by the Agencia Española de Medicamentos y Productos Sanitarios, which oversees clinical trials in Spain.<|>8)\n##\n(\"relationship\"<|>ENSAYOS CLÍNICOS<|>REAL DECRETO 1090/2015<|>Clinical trials are governed by Real Decreto 1090/2015, which sets the legal framework for their conduct in Spain.<|>9)\n##\n(\"relationship\"<|>ESTUDIOS POSTAUTORIZACIÓN<|>AGENCIA ESPAÑOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS<|>Post-authorization studies are also regulated by the Agencia Española de Medicamentos y Productos Sanitarios to ensure safety and efficacy of approved medications.<|>8)\n##\n(\"relationship\"<|>ENSAYOS CLÍNICOS<|>DECLARACIÓN DE HELSINKI<|>Clinical trials must adhere to the ethical principles outlined in the Declaration of Helsinki to protect human subjects.<|>9)\n##\n(\"relationship\"<|>ENSAYOS CLÍNICOS<|>LEY ORGÁNICA 15/1999<|>Clinical trials must comply with Ley Orgánica 15/1999 to ensure the protection of personal data of participants.<|>8)\n##\n(\"relationship\"<|>ESTUDIOS POSTAUTORIZACIÓN<|>REAL DECRETO 577/2013<|>Post-authorization studies are regulated under Real Decreto 577/2013, which focuses on pharmacovigilance of approved medications.<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: un impacto en los proyectos rela-\ncionados con la nutrición clínica, especialmente cuan-\ndo los estudios se centran en el uso de fármacos y\nnutrición parenteral. En estas situaciones, los ensayos\nclínicos o los observacionales estarán regulados por la\nsiguiente legislación:\n\nEnsayos clínicos: La legislación que regula estos en-\nsayos, independientemente del estado de autorización\ndel fármaco, es el Real Decreto 1090/2015, de 4 de\ndiciembre, por el que se regulan los ensayos clínicos\ncon medicamentos, los Comités de Ética de la Investi-\ngación con medicamentos y el Registro Español de Es-\ntudios Clínicos. El pasado mes de enero de 2016 entró\nen vigor este Real Decreto, cuyos objetivos principales\nson desarrollar las disposiciones específicas para la\naplicación en España del Reglamento (UE) n.º 536/2014\ndel Parlamento Europeo y del Consejo, de 16 de abril\nde 2014, sobre los ensayos clínicos de medicamentos\nde uso humano y Regular los Comités de Ética de la\n\nInvestigación con medicamentos, así como el Registro\nespañol de estudios clínicos, conformado tanto por los\nensayos clínicos como por los estudios postautoriza-\nción observacionales que se realicen con medicamen-\ntos de uso humano. Solo se podrá iniciar un ensayo\nclínico objeto de esta regulación cuando el Comité de\nÉtica de Investigación Médica y la Agencia Española de\nMedicamentos y Productos Sanitarios hayan considera-\ndo que se cumplen la totalidad de las siguientes condi-\nciones: 1) El ensayo clínico es ética y metodológica-\nmente correcto y está diseñado para que se obtengan\ndatos fiables y sólidos. 2) Los beneficios para el sujeto\ndel ensayo o para la salud pública esperados justifican\nlos riesgos y los inconvenientes previsibles, y se super-\nvisa de forma constante el cumplimiento de esta con-\ndición. 3) Se obtiene y documenta el consentimiento\ninformado de cada uno de los sujetos del ensayo, libre-\nmente expresado, antes de su inclusión en el ensayo. 4)\nSe respetan los derechos del sujeto a su integridad físi-\nca y mental, y a su intimidad, y se protegen los datos\nde carácter personal que le conciernen, de acuerdo con\nla Ley Orgánica 15/1999, de 13 de diciembre, de Pro-\ntección de Datos de Carácter Personal. 5) El ensayo clí-\nnico ha sido diseñado para reducir al mínimo posible el\ndolor, la incomodidad, el miedo y cualquier otro riesgo\nprevisible para los sujetos del ensayo. 6) La atención\nsanitaria que se dispensa y las decisiones médicas que\nse adoptan sobre las personas son responsabilidad de\nun médico, de un odontólogo debidamente cualifica-\ndo o de otro profesional sanitario, siempre en orden a\nsus competencias para ofrecer los cuidados necesarios.\n7) Se han facilitado al sujeto de ensayo o, si este no es\ncapaz de dar su consentimiento informado, a su repre-\nsentante legalmente designado, los datos de contacto\nde una entidad que puede proporcionarle información\nadicional en caso de necesidad. 8) No se ha ejercido en\nlos sujetos del ensayo influencia indebida alguna, in-\nclusive de carácter económico, para que participen en\nel ensayo. 9) Se ha contratado el seguro o garantía fi-\nnanciera; los ensayos clínicos deberán realizarse de\nacuerdo con la Declaración de Helsinki sobre los princi-\npios éticos para las investigaciones médicas en seres\nhumanos. 10) En el caso de que en el ensayo clínico se\nprevea la recogida de muestras biológicas se establece-\nrán las previsiones oportunas para que una vez finaliza-\ndo el ensayo su utilización en investigación se adecue a\nlo previsto en el Real Decreto 1716/2011.\n\nEstudios postautorización (EPA) observacionales: Se\ndefinen como las investigaciones con medicamentos\nde uso aprobado por la Agencia Española del Medica-\nmento y diseñados como estudios no experimentales.\nLa legislación que regula los EPA es el Real Decreto\n577/2013, de 26 de julio, por el que se regula la farma-\ncovigilancia de medicamentos de uso humano, el Ane-\nxo VI de la Circular 15/2002 de la Agencia Española del\nMedicamento (AEM) y la legislación específica de cada\n---\n# BLOQUE: NUTRICIÓN Y ASPECTOS LEGALES\n\ncomunidad autónoma. A diferencia de los ensayos clínicos, la legislación de los estudios observacionales es menos estricta, diferenciándose principalmente en los\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}